Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours

被引：0
作者：
Daniel M. Huse
Margaret von Mehren
Gregory Lenhart
Heikki Joensuu
Charles Blanke
Weiwei Feng
Stan Finkelstein
George Demetri
机构：
[1] Thomson Medstat,Department of Medical Oncology
[2] Fox Chase Cancer Center,Department of Oncology, Helsinki University
[3] Helsinki University Central Hospital,MIT Sloan School of Management
[4] The Oregon Health and Science University Cancer Institute,Dana
[5] Novartis Pharmaceuticals Corporation,Farber Cancer Institute
[6] Oncology,undefined
[7] Harvard-MIT Division of Health Sciences and Technology,undefined
[8] Center for Sarcoma and Bone Oncology,undefined
来源：
Clinical Drug Investigation | 2007年 / 27卷
关键词：
Pancreatic Cancer; Imatinib; National Comprehensive Cancer Network; National Comprehensive Cancer Network; Imatinib Mesylate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is partly dependent on reimbursement by third-party payers in many countries. The objective of this study was to estimate the cost effectiveness of imatinib mesylate in the treatment of GIST.
引用
收藏
页码：85 / 93
页数：8
相关论文
共 64 条
  • [1] Blay J.Y.(2005)Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO Ann Oncol 16 566-78
  • [2] Bonvalot S.(2002)Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459-65
  • [3] Casali P.(2000)Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management Ann Surg Oncol 7 705-12
  • [4] Fletcher C.D.(2005)Gastrointestinal stromal tumors and the evolution of targeted therapy Clin Adv Hematol Oncol 3 647-57
  • [5] Berman J.J.(2002)Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review Hum Pathol 33 478-83
  • [6] Corless C.(1995)Primary gastrointestinal sarcomas: analysis of prognostic variables Ann Surg Oncol 2 26-31
  • [7] Pidhorecky I.(2000)Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51-8
  • [8] Cheney R.T.(2006)Gastrointestinal stromal tumors: three perspectives on current diagnosis and therapy Eur J Cancer Suppl 4 1-3
  • [9] Kraybill W.G.(2002)Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472-80
  • [10] Sanborn R.E.(2002)Safety and efficacy of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 38 S83-7
1234567